Objectives To investigate the clinical efficacy of exercise management combined with paricalcitol on secondary hyperparathyroidism (SHPT) and on the fibroblast growth factor 23 (FGF23)-Klotho axis in maintenance hemodialysis (MHD) patients Methods Forty MHD patients were randomly divided into drug group (using paricalcitol) and combined group (using exercise combined with paricalcitol). Serum calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), FGF23 and Klotho were compared between the two groups before treatment, and after treatment for 12 weeks and 24 weeks. Results Along with the increase of treatment time, serum P and iPTH were lower in combined group than in drug group (F=4.614 and 4.144; P=0.038 and 0.049), Klotho increased in combined group (F=27.744; P=0.007), and serum Ca, ALP and FGF23 had no differences between the two groups (F=0.004, 0.379 and 0.115 respectively; P=0.070, 0.542 and 0.501 respectively). Before the treatment and after the treatment for 12 and 24 weeks, serum P, iPTH and ALP in the two groups showed statistical differences and decrease trend at the three time points (F=31.395, 60.159 and 38.469 respectively; P<0.001), while serum Ca and Klotho in the two groups revealed statistical differences and increase trend at the three time points (F=21.368 and 5.268; P<0.001); there were reciprocal effects between serum levels of P, Ca, iPTH, ALP and Klotho in the two groups and treatment period (F=6.013, 0.208, 5.321, 4.618 and 5.813 respectively; P=0.008, 0.013, 0.013, 0.028 and 0.013 respectively), but serum FGF23 in the two groups and treatment period did not have such reciprocal effect (F=2.637, P=0.645). Conclusions Exercise combined with paricalciferol increased serum Klotho level and decreased serum P and iPTH levels, through which the progressive course of SHPT can be controlled.
ZOU Chun-Bo
,
SU Ting-Ting
,
ZHANG Shu-Yan
,
LIU Hai-Fei
. Exercise management combined with paricalciferol increases serum Klotho and improves secondary hyperparathyroidism[J]. Chinese Journal of Blood Purification, 2023
, 22(02)
: 114
-118
.
DOI: 10.3969/j.issn.1671-4091.2023.02.008
参考文献
[1]Elias R M, Dalboni M A, Coelho A C E, et al. CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets[J]. Current osteoporosis reports, 2018,16(6):693-702.
[2]Mizobuchi M, Ogata H, Koiwa F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment[J]. Ther Apher Dial, 2019,23(4):309-318.
[3]de Boer I H, Caramori M L, Chan J C N, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease[J]. Kidney international, 2020,98(4):S1-S115.
[4]Zoccali C, Curatola G, Panuccio V, et al. Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial[J]. Hypertension, 2014,64(5):1005-1011.
[5]KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF GLOMERULAR DISEASES. Kidney International (2021) 100, S1–S276.
[6]Krajisnik T, Olauson H, Mirza M A I, et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients[J]. Kidney international, 2010,78(10):1024-1032.
[7]Liao H, Huang T, Chang Y, et al. Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production[J]. International journal of molecular sciences, 2019,20(8):2044.
[8]Gardinier J D, Rostami N, Juliano L, et al. Bone adaptation in response to treadmill exercise in young and adult mice[J]. Bone Reports, 2018,8:29-37.
[9]LEE A S, JUNG Y J, THANH T N, et al. Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway[J]. International journal of molecular medicine, 2016,37(4):1023-1029.
[10]Schefer V, Talan M I. Oxygen consumption in adult and aged C57BL/6J mice during acute treadmill exercise of different intensity[J]. Experimental gerontology, 1996,31(3):387-392.
[11]Van Craenenbroeck A H, Van Craenenbroeck E M, Kouidi E, et al. Vascular effects of exercise training in CKD: current evidence and pathophysiological mechanisms[J]. Clin J Am Soc Nephrol, 2014,9(7):1305-1318.
[12]Avin K G, Coen P M, Huang W, et al. Skeletal muscle as a regulator of the longevity protein, Klotho[J]. Frontiers in physiology, 2014,5:189.
[13]Bergmark B A, Udell J A, Morrow D A, et al. Klotho, fibroblast growth factor‐23, and the renin–angiotensin system — an analysis from the PEACE trial[J]. European journal of heart failure, 2019,21(4):462-470.
[14]Fakhrpour R, Hamid Tayebi Khosroshahi H, Ebrahim K, Ahmadizad S, Abbasnejad M, Mesgari Abbasi M, Ghanbari A, Yaghoobi SF. Effect of Sixteen Weeks Combined Training on FGF-23, Klotho, and Fetuin-A Levels in Patients on Maintenance Hemodialysis. Iran J Kidney Dis. 2020 May;14(3):212-218. Erratum in: Iran J Kidney Dis. 2020 Jul;14(4):329. PMID: 32361698.
[15]Johansen K L. Exercise and Chronic Kidney Disease: Current Recommendations[Z]. Cham: Adis International, 2005: 35, 485-499.
[16]戴珊珊, 马迎春. 透析中递增式抗阻运动对维持性血液透析患者营养状况及体脂成分的影响[J]. 中华肾脏病杂志, 2021,37(05):434-437.
[17]Heiwe S, Jacobson S H. Exercise Training in Adults With CKD: A Systematic Review and Meta-analysis[J]. American Journal of Kidney Diseases, 2014,64(3):383-393.
[18]徐帅,李世昌,陈祥和.运动对雄性小鼠骨内分泌FGF23—Klotho/FGFR1轴及相关因子表达的影响[J].中国运动医学杂志,2019,38(10):882-889.DOI:10.16038/j.1000-6710.2019.10.009.
[19]Heiwe S, Jacobson S H. Exercise Training in Adults With CKD: A Systematic Review and Meta-analysis[J]. American Journal of Kidney Diseases, 2014,64(3):383-393.
[20] Krajisnik T, Olauson H, Mirza M A I, et al. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients[J]. Kidney international, 2010,78(10):1024-1032.
